The effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional constipation in children. A randomized, double-blind, placebo-controlled, multicentre trial

Wegner, Agnieszka; Banaszkiewicz, Aleksandra; Kierkuś, Jarosław; Landowski, Piotr; Korlatowicz-Bilar, Anna; Więcek, Sabina; Kwiecień, Jarosław; Gawrońska, Agnieszka; Dembiński, Łukasz; Czaja‐Bulsa, Grażyna; Socha, Piotr

doi:10.1016/j.clinre.2018.03.008

Cited by 38 publications

(34 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that the effect of the treatment can vary according to the combination of the synbiotics used [ 28 ]. The combination of L. reuteri DSM 17938 plus prebiotics in the treatment of constipation has not been investigated; only the combination of probiotics with drugs such as polyethylene glycol and lactulose has been studied without evidence of favorable effects [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy and Chronic Constipation: A Double-Blind Randomized Placebo Controlled Clinical Trial

et al. 2020

View full text Add to dashboard Cite

The main objective was to assess the efficacy of a probiotic (Lactobacillus reuteri DSM 17938), a prebiotic (agave inulin), and a synbiotic on the stool characteristics in children with cerebral palsy and chronic constipation. Thirty-seven children with cerebral palsy and chronic constipation were included. The probiotic group received 1 × 108 colony forming unit (cfu) of L. reuteri DSM 17938 plus placebo, the prebiotic group received 4 g of agave inulin plus placebo, the synbiotic group received L. reuteri DSM 17938 plus agave inulin, and the placebo group received two placebos for 28 days. The probiotic group showed a significant decrease in stool pH (p = 0.014). Stool consistency improved in the prebiotic group (p = 0.008). The probiotic, prebiotic, and synbiotic groups showed a significant improvement in the history of excessive stool retention, the presence of fecal mass in the rectum, and the history of painful defecation. L. reuteri concentration in feces was higher in the probiotic group than in the placebo group (p = 0.001) and showed an inverse correlation with stool pH in the probiotic group (r = −0.762, p = 0.028). This study showed that the use of L. reuteri DSM 17938 and/or agave inulin improved the stool characteristics such as the history of painful defecation and the presence of fecal mass in the rectum against placebo in children with cerebral palsy and chronic constipation.

show abstract

Section: Discussionmentioning

confidence: 99%

Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy and Chronic Constipation: A Double-Blind Randomized Placebo Controlled Clinical Trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…reuteri DSM 17938 in FC (13)(14)(15)(16)(17); however, to our knowledge, no systematic reviews have investigated the function of L.…”

Section: Objectivesmentioning

confidence: 99%

“…The reference lists of articles identified from the search were reviewed to identify any other eligible articles. Characteristics of the included articles (13)(14)(15)(16)(17) are shown in Table 1.…”

Section: Study Selectionmentioning

confidence: 99%

Effectiveness of a Probiotic for Functional Chronic Constipation: A Meta-analysis of Randomized Controlled Trials

Wu¹

2020

Iran J Pediatr

View full text Add to dashboard Cite

Background: The metabolic effects of Lactobacillus reuteri DSM 17938 administration in the treatment of functional chronic constipation are unknown. Objectives: The purpose of this review is to investigate the function of L. reuteri DSM 17938 in bowel movements and stool consistency in children and adults diagnosed with functional chronic constipation. Methods: Five electronic databases were used to search for the English version of Randomized Controlled Trials (RCTs) published between 2000 and 2018 that investigated the metabolic functions of 4–8 weeks of a dietary L. reuteri DSM 17938 intervention in children and adults diagnosed with functional chronic constipation. The risk of bias was evaluated in eligible studies, and a random-effects model was used to perform a meta-analysis for qualitative and quantitative analyses. Results: Five high-quality RCTs involving 737 participants were included in the review. L. reuteri DSM 17938 supplementation was effective in increasing bowel movements (mean difference = 1.12; 95% CI 0.85, 1.39, P < 0.00001) in patients with functional chronic constipation. However, no significant differences in stool consistency from baseline were observed following L. reuteri DSM 17938 supplementation (0.98; 95% CI 0.66, 1.44, P = 0.90). Conclusions: There were significant differences in bowel movements between the experimental and placebo groups, and no significant differences in stool consistency. In addition, there were no adverse effects of the L. reuteri DSM 17938 treatment reported. These results demonstrate the beneficial effects of L. reuteri DSM 17938 in functional chronic constipation patients in comparison with placebo.

show abstract

“…Interestingly, certain human microbiota species appear to influence specific and relevant gut functions. For instance, F. prausnitzii may operate as a modulator of colonic hypersensitivity [ 27 ] and Lactobacillus reuteri as a regulator of colonic transit [ 28 ]. Unfortunately, progress in this area is hampered by the absence of good biomarkers of healthy microbiota to predict disease or to help us monitor responses to agents acting of human gut microbiota.…”

Section: Approaching Ibs Therapy From a Pathophysiological Perspectivmentioning

confidence: 99%

Mechanism-Oriented Therapy of Irritable Bowel Syndrome

Malagelada¹,

Malagelada²

2016

Adv Ther

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a common and well-accepted diagnosis but often imprecisely applied to patients in usual clinical practice. Diagnosis is entirely based on symptom criteria that tend to include broad strata of abdominal complainers. Established criteria for diagnosis are strictly followed in controlled clinical trials for new therapeutic agents, but physicians are more lax in the clinic. Predictably, in light of the above ambiguities, many pathogenetic mechanisms and pathophysiological disturbances appear to be involved in IBS, but so far no mechanism-based subgroupings to guide specific therapy have been soundly established. Thus, diverse therapeutic approaches coexist and are discretionally prescribed by attending clinicians on the basis of major manifestations (i.e., diarrhea-predominance or constipation-predominance), more or less apparent psychological disturbances, and patient preferences (pharmacological versus dietary or microbiological approaches). In this review, we have attempted to update scientific knowledge about the more relevant disease mechanisms involved and relate this more fundamental basis to the various treatment options available today.

show abstract

The effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional constipation in children. A randomized, double-blind, placebo-controlled, multicentre trial

Cited by 38 publications

References 19 publications

Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy and Chronic Constipation: A Double-Blind Randomized Placebo Controlled Clinical Trial

Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy and Chronic Constipation: A Double-Blind Randomized Placebo Controlled Clinical Trial

Effectiveness of a Probiotic for Functional Chronic Constipation: A Meta-analysis of Randomized Controlled Trials

Mechanism-Oriented Therapy of Irritable Bowel Syndrome

Contact Info

Product

Resources

About